CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 90,122	$ 92,055	$ 101,907
Operating costs and expenses:
Cost of goods sold	33,768	21,635	24,897
Research and development	114,162	218,323	400,269
General and administrative	77,417	92,333	122,844
Restructuring, impairment and costs of terminated program	51,958	135,930	0
Impairment of goodwill	76,501	0	0
Total operating costs and expenses	353,806	468,221	548,010
Loss from operations	(263,684)	(376,166)	(446,103)
Non-operating income (expense):
Change in fair value of development derivative liability	0	33,427	(8,023)
Non-cash interest expense on liabilities related to the sales of future royalties	(25,334)	(28,911)	(47,313)
Loss on revaluation of liability related to the sale of future royalties	0	0	(24,410)
Interest income	19,009	6,783	2,731
Other income (expense), net	(6,247)	(116)	(162)
Total non-operating income (expense), net	(12,572)	11,183	(77,177)
Loss before provision for income taxes	(276,256)	(364,983)	(523,280)
Provision (benefit) for income taxes	(200)	3,215	557
Net loss	$ (276,056)	$ (368,198)	$ (523,837)
Basic net loss per share (in dollars per share)	$ (1.45)	$ (1.97)	$ (2.86)
Diluted net loss per share (in dollars per share)	$ (1.45)	$ (1.97)	$ (2.86)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	190,001	187,138	183,298
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	190,001	187,138	183,298
Product sales
Revenue:
Total revenue	$ 20,681	$ 20,348	$ 23,725
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	68,921	69,794	77,746
License, collaboration and other revenue
Revenue:
Total revenue	$ 520	$ 1,913	$ 436